The effect of Captopril on benign and malignant reactions in irradiated rat skin
- PMID: 2198982
- DOI: 10.1259/0007-1285-63-749-349
The effect of Captopril on benign and malignant reactions in irradiated rat skin
Abstract
The effect of the angiotensin converting enzyme inhibitor Captopril on the severity of radiation-induced epilation and moist desquamation and the incidence of skin tumours was determined for up to 52 weeks in male rats. The irradiation consisted of a range of single doses (0, 10, 20, 30 Gy) of 60Co gamma rays to a 3.5 cm2 right hemithorax port. Half of each radiation dose group consumed control powdered chow, and half consumed chow containing Captopril (50 mg/kg/day) continuously after irradiation. There were time- and radiation-dose-dependent increases in all three skin reactions. Rats exposed to 10 Gy exhibited a mild and transient epilation, but no moist desquamation or neoplasia in the radiation port. In animals exposed to 30 Gy, however, epilation began at 2 weeks after irradiation, reached a peak at approximately 7 weeks, then persisted essentially unchanged through 52 weeks. Captopril had no significant effect on the epilation reaction. Two waves of moist desquamation were observed after 30 Gy. The first appeared at 3 weeks after irradiation, reached a peak from 6-10 weeks, then subsided partially but significantly from 12-26 weeks. The second wave of moist desquamation began at 26-28 weeks, often was ulcerative, and occasionally was accompanied by the appearance of tumours in the irradiated volume. Captopril significantly (p less than 0.05) reduced the severity of both phases of the moist desquamation reaction after 30 Gy, and reduced the percentage of animals exhibiting the most severe desquamation score (involving 50% of the radiation port). Of particular interest was the observation that Captopril also reduced the incidence of tumours. Of the 14 tumours detected, all were malignant (fibrosarcomas, squamous cell carcinomas), and only three (p less than 0.05) occurred in rats receiving Captopril. Multiple tumours (three cases), tumours induced by 20 Gy (three cases), and tumours appearing before 6 months (one case) were observed only in rats consuming control diet, never in Captopril-treated animals. Animals which developed tumours in the second 6 months post-irradiation exhibited significantly more severe moist desquamation during the first 6 months than did the tumour-free members of their treatment group. Thus Captopril, known to ameliorate acute lung damage in irradiated rats, also reduces chronic benign and malignant skin reactions in the radiation treatment field.
Similar articles
-
Radiation pneumonitis in rats and its modification by the angiotensin-converting enzyme inhibitor captopril evaluated by high-resolution computed tomography.Radiat Res. 1993 Jul;135(1):81-7. Radiat Res. 1993. PMID: 8327665
-
Pentoxifylline does not spare acute radiation reactions in rat lung and skin.Radiat Res. 1992 Jan;129(1):107-11. Radiat Res. 1992. PMID: 1728051
-
Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker.Int J Radiat Biol. 2000 Apr;76(4):523-32. doi: 10.1080/095530000138538. Int J Radiat Biol. 2000. PMID: 10815633
-
Radiotherapy of the rhabdomyosarcoma R1H of the rat: recovery from radiation injury in tumour and skin.Radiother Oncol. 1992 Feb;23(2):105-10. doi: 10.1016/0167-8140(92)90341-q. Radiother Oncol. 1992. PMID: 1546185 Review.
-
The skin: its structure and response to ionizing radiation.Int J Radiat Biol. 1990 Apr;57(4):751-73. doi: 10.1080/09553009014550911. Int J Radiat Biol. 1990. PMID: 1969905 Review.
Cited by
-
New approaches to radiation protection.Front Oncol. 2015 Jan 20;4:381. doi: 10.3389/fonc.2014.00381. eCollection 2014. Front Oncol. 2015. PMID: 25653923 Free PMC article. Review.
-
Carcinogenicity of antihypertensive therapy.Curr Hypertens Rep. 2002 Jun;4(3):195-201. doi: 10.1007/s11906-002-0007-4. Curr Hypertens Rep. 2002. PMID: 12003701 Review.
-
Repurposing Pharmaceuticals Previously Approved by Regulatory Agencies to Medically Counter Injuries Arising Either Early or Late Following Radiation Exposure.Front Pharmacol. 2021 May 10;12:624844. doi: 10.3389/fphar.2021.624844. eCollection 2021. Front Pharmacol. 2021. PMID: 34040517 Free PMC article. Review.
-
Low-dose enalapril in the treatment of surgical cutaneous hypertrophic scar and keloid--two case reports and literature review.MedGenMed. 2006 Dec 20;8(4):60. MedGenMed. 2006. PMID: 17415337 Free PMC article. Review.
-
Radiation countermeasure agents: an update (2011-2014).Expert Opin Ther Pat. 2014 Nov;24(11):1229-55. doi: 10.1517/13543776.2014.964684. Epub 2014 Oct 14. Expert Opin Ther Pat. 2014. PMID: 25315070 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical